ALKERMES | ALKS - Assets



ALKERMES reported $2.25B in Assets for its fiscal quarter ending in June of 2025.


Assets Change Date
AbbVie USD 136.17B 1B Mar/2025
Acadia Pharmaceuticals USD 1.23B 93.19M Jun/2025
ALKERMES USD 2.25B 170.83M Jun/2025
Amgen USD 87.9B 1.47B Jun/2025
Biogen USD 28.33B 297.1M Jun/2025
BioMarin Pharmaceutical USD 7.46B 309.33M Jun/2025
Bristol-Myers Squibb USD 94.68B 2.25B Jun/2025
Eli Lilly USD 100.92B 11.53B Jun/2025
Gilead Sciences USD 55.72B 713M Jun/2025
Ionis Pharmaceuticals USD 2.99B 172.18M Jun/2025
J&J USD 193.67B 13.57B Mar/2025
Malin Corporation EUR 198.5M 70.1M Dec/2024
Merck USD 117.52B 2.4B Jun/2025
Neurocrine Biosciences USD 3.89B 202.1M Jun/2025
Otsuka Holdings JPY 3.79T 96.25B Jun/2025
Pfizer USD 206.1B 1.93B Jun/2025
Regeneron Pharmaceuticals USD 38.22B 674M Jun/2025
Vertex Pharmaceuticals USD 24.04B 1.16B Jun/2025